Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Active Not Recruiting Phase 2 Trials for Cytarabine (DB00987)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00390793Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.Treatment